{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T10:04:27Z","timestamp":1725012267170},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,4,10]],"date-time":"2011-04-10T00:00:00Z","timestamp":1302393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2474-12-71","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T06:20:00Z","timestamp":1302589200000},"source":"Crossref","is-referenced-by-count":11,"title":["Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study"],"prefix":"10.1186","volume":"12","author":[{"given":"Gelsomina L","family":"Borromeo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elly","family":"Flitzanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D","family":"Wark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,10]]},"reference":[{"issue":"9","key":"1100_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1172\/JCI0217051","volume":"110","author":"R Lindsay","year":"2002","unstructured":"Lindsay R: Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest. 2002, 110 (9): 1239-1241.","journal-title":"J Clin Invest"},{"issue":"6","key":"1100_CR2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","volume":"18","author":"BE Hillner","year":"2000","unstructured":"Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000, 18 (6): 1378-1391.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1100_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4065\/82.4.516","volume":"82","author":"BG Durie","year":"2007","unstructured":"Durie BG: Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007, 82 (4): 516-517. 10.4065\/82.4.516. author reply 517-518","journal-title":"Mayo Clin Proc"},{"issue":"2 Suppl 6","key":"1100_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0093-7754(01)90262-3","volume":"28","author":"JR Berenson","year":"2001","unstructured":"Berenson JR: Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin Oncol. 2001, 28 (2 Suppl 6): 25-34. 10.1016\/S0093-7754(01)90262-3.","journal-title":"Semin Oncol"},{"issue":"9","key":"1100_CR5","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1359\/jbmr.090310","volume":"24","author":"PD Delmas","year":"2009","unstructured":"Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R: Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009, 24 (9): 1544-1551. 10.1359\/jbmr.090310.","journal-title":"J Bone Miner Res"},{"issue":"18","key":"1100_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356 (18): 1809-1822. 10.1056\/NEJMoa067312.","journal-title":"N Engl J Med"},{"issue":"9671","key":"1100_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009, 373 (9671): 1253-1263. 10.1016\/S0140-6736(09)60250-6.","journal-title":"Lancet"},{"issue":"9527","key":"1100_CR8","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C: Osteoporosis. Lancet. 2006, 367 (9527): 2010-2018. 10.1016\/S0140-6736(06)68891-0.","journal-title":"Lancet"},{"key":"1100_CR9","doi-asserted-by":"crossref","unstructured":"Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008, CD001155-1","DOI":"10.1002\/14651858.CD001155.pub2"},{"key":"1100_CR10","doi-asserted-by":"crossref","unstructured":"Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A, Robinson V, Wells G, Tugwell P, Adachi JD: Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev. 2003, CD004523-4","DOI":"10.1002\/14651858.CD004523"},{"key":"1100_CR11","doi-asserted-by":"crossref","unstructured":"Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P: Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008, CD004523-1","DOI":"10.1002\/14651858.CD004523.pub3"},{"issue":"6","key":"1100_CR12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/jbmr.5650100617","volume":"10","author":"DH Schweitzer","year":"1995","unstructured":"Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE: Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 1995, 10 (6): 956-962. 10.1002\/jbmr.5650100617.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1100_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ncpendmet0121","volume":"2","author":"RD Chapurlat","year":"2006","unstructured":"Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006, 2 (4): 211-219. 10.1038\/ncpendmet0121. quiz following 238","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1100_CR14","unstructured":"Pazianas M, Cooper C, Ebetino FH, Russell RG: Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 6: 325-343."},{"issue":"4","key":"1100_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00774-009-0047-9","volume":"27","author":"S Cetiner","year":"2009","unstructured":"Cetiner S, Sucak GT, Kahraman SA, Aki SZ, Kocakahyaoglu B, Gultekin SE, Cetiner M, Haznedar R: Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab. 2009, 27 (4): 435-443. 10.1007\/s00774-009-0047-9.","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"1100_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","volume":"112","author":"T Fehm","year":"2009","unstructured":"Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M: Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol. 2009, 112 (3): 605-609. 10.1016\/j.ygyno.2008.11.029.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1100_CR17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5694\/j.1326-5377.2005.tb06761.x","volume":"182","author":"G Carter","year":"2005","unstructured":"Carter G, Goss AN, Doecke C: Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005, 182 (8): 413-415.","journal-title":"Med J Aust"},{"issue":"8","key":"1100_CR18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","volume":"182","author":"PM Purcell","year":"2005","unstructured":"Purcell PM, Boyd IW: Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005, 182 (8): 417-418.","journal-title":"Med J Aust"},{"issue":"2","key":"1100_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","volume":"34","author":"JV Bagan","year":"2005","unstructured":"Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C: Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005, 34 (2): 120-123. 10.1111\/j.1600-0714.2004.00269.x.","journal-title":"J Oral Pathol Med"},{"issue":"9","key":"1100_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003, 61 (9): 1115-1117. 10.1016\/S0278-2391(03)00720-1.","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"1100_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/07357900802208608","volume":"27","author":"JB Aragon-Ching","year":"2009","unstructured":"Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD: Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009, 27 (2): 221-226. 10.1080\/07357900802208608.","journal-title":"Cancer Invest"},{"key":"1100_CR22","doi-asserted-by":"crossref","unstructured":"Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 68 (2): 243-253. 10.1016\/j.joms.2009.03.050.","DOI":"10.1016\/j.joms.2009.03.050"},{"issue":"5","key":"1100_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","volume":"63","author":"JW Hellstein","year":"2005","unstructured":"Hellstein JW, Marek CL: Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005, 63 (5): 682-689. 10.1016\/j.joms.2005.01.010.","journal-title":"J Oral Maxillofac Surg"},{"issue":"7","key":"1100_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","volume":"65","author":"EP Wang","year":"2007","unstructured":"Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ: Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007, 65 (7): 1328-1331. 10.1016\/j.joms.2007.03.006.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"1100_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie BG, Katz M, Crowley J: Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005, 353 (1): 99-102. 10.1056\/NEJM200507073530120. discussion 199-102","journal-title":"N Engl J Med"},{"issue":"6","key":"1100_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008, 23 (6): 826-836. 10.1359\/jbmr.080205.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1100_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tripleo.2004.10.001","volume":"99","author":"CA Migliorati","year":"2005","unstructured":"Migliorati CA: Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005, 99 (2): 135-10.1016\/j.tripleo.2004.10.001.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"13","key":"1100_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/jnci\/djm025","volume":"99","author":"GS Wilkinson","year":"2007","unstructured":"Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS: Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst. 2007, 99 (13): 1016-1024. 10.1093\/jnci\/djm025.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1100_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JOP.2.1.7","volume":"2","author":"S Ruggiero","year":"2006","unstructured":"Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V: Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006, 2 (1): 7-14. 10.1200\/JOP.2.1.7.","journal-title":"J Oncol Pract"},{"issue":"Suppl 2","key":"1100_CR30","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1007\/s00586-003-0622-z","volume":"12","author":"H Fleisch","year":"2003","unstructured":"Fleisch H: Bisphosphonates in osteoporosis. Eur Spine J. 2003, 12 (Suppl 2): S142-146. 10.1007\/s00586-003-0622-z.","journal-title":"Eur Spine J"},{"issue":"24","key":"1100_CR31","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","volume":"26","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, Huryn JM: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008, 26 (24): 4037-4038. 10.1200\/JCO.2007.15.5424.","journal-title":"J Clin Oncol"},{"key":"1100_CR32","doi-asserted-by":"crossref","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28 (35): 5132-5139. 10.1200\/JCO.2010.29.7101.","DOI":"10.1200\/JCO.2010.29.7101"},{"issue":"4","key":"1100_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00428-006-0261-y","volume":"449","author":"T Hansen","year":"2006","unstructured":"Hansen T, Kirkpatrick CJ, Walter C, Kunkel M: Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis--a paradoxical observation?. Virchows Arch. 2006, 449 (4): 448-454. 10.1007\/s00428-006-0261-y.","journal-title":"Virchows Arch"},{"issue":"3","key":"1100_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.tripleo.2004.08.001","volume":"98","author":"MS Greenberg","year":"2004","unstructured":"Greenberg MS: Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004, 98 (3): 259-260. 10.1016\/j.tripleo.2004.08.001.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"1100_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev.med.60.063007.134350","volume":"60","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Mehrotra B: Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009, 60: 85-96. 10.1146\/annurev.med.60.063007.134350.","journal-title":"Annu Rev Med"},{"key":"1100_CR36","doi-asserted-by":"crossref","unstructured":"Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G: The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 141 (11): 1365-1370.","DOI":"10.14219\/jada.archive.2010.0082"},{"key":"1100_CR37","doi-asserted-by":"crossref","unstructured":"Jung TI, Hoffmann F, Glaeske G, Felsenberg D: Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol. 136 (3): 363-370. 10.1007\/s00432-009-0662-9.","DOI":"10.1007\/s00432-009-0662-9"},{"key":"1100_CR38","volume-title":"Canberra: Australian Institute of Health and Welfare (Dental Statistics and Research Series No 34)","author":"GSA Slade","year":"2007","unstructured":"Slade GSA, Roberts-Thompson K: Australia's dental generations: the National Surveyof Adult oral 2004-6. Canberra: Australian Institute of Health and Welfare (Dental Statistics and Research Series No 34). 2007"},{"key":"1100_CR39","volume-title":"National Health Survey: Summary of results, Australia","author":"Statistics ABo","year":"2004","unstructured":"Statistics ABo: National Health Survey: Summary of results, Australia. 2004"},{"issue":"3","key":"1100_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007, 65 (3): 415-423. 10.1016\/j.joms.2006.10.061.","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"1100_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0022-3913(09)00049-3","volume":"101","author":"Y Takagi","year":"2009","unstructured":"Takagi Y, Sumi Y, Harada A: Osteonecrosis associated with short-term oral administration of bisphosphonate. J Prosthet Dent. 2009, 101 (5): 289-292. 10.1016\/S0022-3913(09)00049-3.","journal-title":"J Prosthet Dent"},{"issue":"10","key":"1100_CR42","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007, 22 (10): 1479-1491. 10.1359\/jbmr.0707onj.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1100_CR43","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1177\/00220345840630050701","volume":"63","author":"F Vinckier","year":"1984","unstructured":"Vinckier F, Vermylen J: Wound healing following dental extractions in rabbits: effects of tranexamic acid, warfarin anti-coagulation, and socket packing. J Dent Res. 1984, 63 (5): 646-649. 10.1177\/00220345840630050701.","journal-title":"J Dent Res"},{"issue":"4","key":"1100_CR44","first-page":"E336","volume":"12","author":"J Bagan","year":"2007","unstructured":"Bagan J, Blade J, Cozar JM, Constela M, Garcia Sanz R, Gomez Veiga F, Lahuerta JJ, Lluch A, Massuti B, Morote J: Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007, 12 (4): E336-340.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"1100_CR45","doi-asserted-by":"crossref","unstructured":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007, 65 (3): 369-376. 10.1016\/j.joms.2006.11.003.","DOI":"10.1016\/j.joms.2006.11.003"},{"issue":"5 Suppl","key":"1100_CR46","first-page":"2","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009, 67 (5 Suppl): 2-12.","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"1100_CR47","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","volume":"35","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J. 2009, 35 (3): 119-130. 10.1111\/j.1747-4477.2009.00213.x.","journal-title":"Aust Endod J"},{"issue":"4","key":"1100_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","volume":"102","author":"SL Ruggiero","year":"2006","unstructured":"Ruggiero SL, Fantasia J, Carlson E: Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006, 102 (4): 433-441. 10.1016\/j.tripleo.2006.06.004.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"2","key":"1100_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","volume":"32","author":"Y Assouline-Dayan","year":"2002","unstructured":"Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME: Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002, 32 (2): 94-124.","journal-title":"Semin Arthritis Rheum"},{"issue":"7347","key":"1100_CR50","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bmj.324.7347.1183","volume":"324","author":"P Edwards","year":"2002","unstructured":"Edwards P, Roberts I, Clarke M, DiGuiseppi C, Pratap S, Wentz R, Kwan I: Increasing response rates to postal questionnaires: systematic review. Bmj. 2002, 324 (7347): 1183-10.1136\/bmj.324.7347.1183.","journal-title":"Bmj"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-12-71\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-12-71.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-12-71","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-12-71.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T04:40:41Z","timestamp":1592455241000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-12-71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,10]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1100"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-12-71","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,10]]},"article-number":"71"}}